Developer docs
API playgroundTry for free, no card

Search company profiles

Definiens

Full company profile

uuid000d5bs

Namestring
Definiens
Legal namestring
Definians AG
Websiteurl
definiens.com
Company typeenum
Private
Founded yearint
1994
Short descriptiontext

Definiens AG, founded in 1994 in Munich, Germany, develops software for biomedical image analysis in digital pathology, serving biopharma, clinical research, and diagnostics customers seeking automated quantitative image interpretation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMunich, Germany
HQ citystring
Munich
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology software, biomedical image analysis, tissue image quantification, biomarker discovery software, healthcare data mining
Industry3 codes
1Medical Imaging AI
CodeHDAAAEAHPrimaryYes
2Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
CodeHLAAALAOPrimaryNo
3AI/ML Platforms for Drug Discovery & Experiment Optimization
CodeHLAGAJAOPrimaryNo
NAICS code2 codes
  • Software Publishers513210
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Prepackaged Software7372
  • Laboratory Analytical Instruments3826
Product category
Digital Pathology Software
Social media profiles2 records
Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Definiens develops and sells software solutions for quantitative analysis of biomedical images, with a focus on digital pathology and tissue-based diagnostics. Its offerings support research institutions, pharmaceutical companies, and clinical laboratories in automating the interpretation of complex microscopy and histology images for biomarker discovery and diagnostic applications.

Differentiator
Functional benefit
Problem solved
Product and service3 records
1Biomedical Image Analysis Software
CategoryDigital Pathology Software
Description

Software platform for automated quantitative analysis and interpretation of biomedical and tissue images, serving pharmaceutical companies, biotech firms, and clinical research institutions for biomarker discovery and digital pathology applications.

2Biomedical Data Mining Solutions
CategoryHealthcare Data Mining Software
Description

Data mining tools that extract diagnostic and research-relevant insights from large volumes of biomedical image data, used by healthcare and life sciences institutions to support research and diagnostic decisions.

3Predictive Tests
CategoryPredictive Diagnostics
Description

Predictive diagnostic tests enabled by Definiens' biomedical image analysis technology, developed for clinical and pharmaceutical customers seeking image-based predictive biomarkers.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Peers10 records
1PathAI
TypeDirect peer
Description

PathAI develops AI-powered pathology diagnostics and biomarker discovery tools, directly overlapping with Definiens' tissue image analysis and digital pathology focus. Both target biopharma and clinical diagnostics customers with deep-learning-based image interpretation.

2Paige
TypeDirect peer
Description

Paige builds AI applications for pathology, including FDA-cleared diagnostic software for prostate and breast cancer. Its focus on computational pathology directly competes with Definiens in tissue-based image analytics for oncology.

3Proscia
TypeDirect peer
Description

Proscia offers a digital pathology platform with AI-enabled image analysis for life sciences and diagnostics. It overlaps with Definiens in serving pharma R&D and clinical pathology workflows with quantitative image insights.

4Aiforia
TypeDirect peer
Description

Aiforia provides AI-based image analysis software for digital pathology, serving preclinical and clinical researchers in pharma and diagnostics. It competes head-to-head with Definiens in tissue phenotyping and biomarker quantification.

5Visiopharm
TypeDirect peer
Description

Visiopharm delivers image analysis and AI solutions for quantitative digital pathology used in research and clinical diagnostics. Its phenotyping and tissue analysis capabilities overlap directly with Definiens' core offering.

6Indica Labs
TypeDirect peer
Description

Indica Labs develops AI-driven image analysis software for pathology, including HALO platforms used in pharma R&D. Its quantitative tissue analysis capabilities make it a direct functional competitor to Definiens.

7Owkin
TypeEmerging player
Description

Owkin applies AI to pathology and multimodal biomedical data for drug discovery and diagnostics. While broader than Definiens (spanning imaging, clinical, and omics data), it overlaps meaningfully in AI-driven pathology for pharma/biotech.

8Roche Digital Pathology
TypeBroad incumbent
Description

Roche (via Roche Diagnostics and Ventana) offers a comprehensive digital pathology platform including whole-slide imaging and AI image analysis. It is a broad incumbent competing with Definiens across pharma and clinical pathology.

9Philips Digital Pathology
TypeBroad incumbent
Description

Philips provides enterprise digital pathology solutions (IntelliSite) with image management and AI-enabled analysis. As a broad healthcare incumbent, it competes in the same integrated workflow layer as Definiens for hospital and lab deployments.

10Hamamatsu Photonics
TypeBroad incumbent
Description

Hamamatsu supplies whole-slide scanners and digital pathology infrastructure used alongside image analysis software. It is an upstream/imaging incumbent adjacent to Definiens in the digital pathology stack.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Definiens

Digital Pathology Softwaredefiniens.com

Definiens AG, founded in 1994 in Munich, Germany, develops software for biomedical image analysis in digital pathology, serving biopharma, clinical research, and diagnostics customers seeking automated quantitative image interpretation.

Definiens firmographics

Firmographics
Name
Definiens
Legal name
Definians AG
Website
https://definiens.com
Company type
Private
Founded year
1994
Operating status
Operating
Headcount range
51–100 employees
Short description
Definiens AG, founded in 1994 in Munich, Germany, develops software for biomedical image analysis in digital pathology, serving biopharma, clinical research, and diagnostics customers seeking automated quantitative image interpretation.
Ownership category
akta.pro rank

Definiens industry classification

Industry
Product category
Digital Pathology Software
NAICS
Software Publishers (513210), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Prepackaged Software (7372), Laboratory Analytical Instruments (3826)
akta.pro primary industry
Medical Imaging AI (HDAAAEAH)
akta.pro secondary industries
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

  • Digital pathology software
  • Biomedical image analysis
  • Tissue image quantification
  • Biomarker discovery software
  • Healthcare data mining

Where Definiens is headquartered

Location

Headquarters

HQ city
Munich
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Definiens business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Definiens product offering

Product offering

Core offering

Definiens develops and sells software solutions for quantitative analysis of biomedical images, with a focus on digital pathology and tissue-based diagnostics. Its offerings support research institutions, pharmaceutical companies, and clinical laboratories in automating the interpretation of complex microscopy and histology images for biomarker discovery and diagnostic applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biomedical Image Analysis Software Software platform for automated quantitative analysis and interpretation of biomedical and tissue images, serving pharmaceutical companies, biotech firms, and clinical research institutions for biomarker discovery and digital pathology applications.
  • Biomedical Data Mining Solutions Data mining tools that extract diagnostic and research-relevant insights from large volumes of biomedical image data, used by healthcare and life sciences institutions to support research and diagnostic decisions.
  • Predictive Tests Predictive diagnostic tests enabled by Definiens' biomedical image analysis technology, developed for clinical and pharmaceutical customers seeking image-based predictive biomarkers.

Companies that use Definiens

Customer profile

Segments1 record

Ideal customer profiles2 records

Definiens technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Definiens partnerships and signals

Strategic signal

Scale indicators2 records

Definiens competitors and assessment

Company assessment

Direct peers

  • PathAI: PathAI develops AI-powered pathology diagnostics and biomarker discovery tools, directly overlapping with Definiens' tissue image analysis and digital pathology focus. Both target biopharma and clinical diagnostics customers with deep-learning-based image interpretation.
  • Paige: Paige builds AI applications for pathology, including FDA-cleared diagnostic software for prostate and breast cancer. Its focus on computational pathology directly competes with Definiens in tissue-based image analytics for oncology.
  • Proscia: Proscia offers a digital pathology platform with AI-enabled image analysis for life sciences and diagnostics. It overlaps with Definiens in serving pharma R&D and clinical pathology workflows with quantitative image insights.
  • Aiforia: Aiforia provides AI-based image analysis software for digital pathology, serving preclinical and clinical researchers in pharma and diagnostics. It competes head-to-head with Definiens in tissue phenotyping and biomarker quantification.
  • Visiopharm: Visiopharm delivers image analysis and AI solutions for quantitative digital pathology used in research and clinical diagnostics. Its phenotyping and tissue analysis capabilities overlap directly with Definiens' core offering.
  • Indica Labs: Indica Labs develops AI-driven image analysis software for pathology, including HALO platforms used in pharma R&D. Its quantitative tissue analysis capabilities make it a direct functional competitor to Definiens.

Emerging players

  • Owkin: Owkin applies AI to pathology and multimodal biomedical data for drug discovery and diagnostics. While broader than Definiens (spanning imaging, clinical, and omics data), it overlaps meaningfully in AI-driven pathology for pharma/biotech.

Broad incumbents

  • Roche Digital Pathology: Roche (via Roche Diagnostics and Ventana) offers a comprehensive digital pathology platform including whole-slide imaging and AI image analysis. It is a broad incumbent competing with Definiens across pharma and clinical pathology.
  • Philips Digital Pathology: Philips provides enterprise digital pathology solutions (IntelliSite) with image management and AI-enabled analysis. As a broad healthcare incumbent, it competes in the same integrated workflow layer as Definiens for hospital and lab deployments.
  • Hamamatsu Photonics: Hamamatsu supplies whole-slide scanners and digital pathology infrastructure used alongside image analysis software. It is an upstream/imaging incumbent adjacent to Definiens in the digital pathology stack.

Market position

Customer concentration

Definiens social profiles

Digital presence

Definiens financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Definiens leadership team

Management profile

Number of profiles

Profiles3 records

Definiens funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Definiens M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Definiens

What does Definiens do?

Definiens develops and sells software solutions for quantitative analysis of biomedical images, with a focus on digital pathology and tissue-based diagnostics. Its offerings support research institutions, pharmaceutical companies, and clinical laboratories in automating the interpretation of complex microscopy and histology images for biomarker discovery and diagnostic applications.

Is Definiens a public or private company?

Definiens is a private company. It is classified as venture growth investor backed and is currently operating.

When was Definiens founded?

Definiens was founded in 1994. It employs 51 to 100 people.

Where is Definiens based?

Definiens is headquartered in Munich, Germany, in the Europe region.

Who are Definiens's main competitors?

Direct peers on record are PathAI, Paige, Proscia, Aiforia, Visiopharm and Indica Labs. Owkin is listed as an emerging player. Broad incumbents are Roche Digital Pathology, Philips Digital Pathology and Hamamatsu Photonics.

Does Definiens have an API?

No public API is recorded for Definiens.

What industry is Definiens in?

Definiens's product category is Digital Pathology Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 513210 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comDigital Pathology Market Growing at CAGR 8.24% Led by Sectra, Proscia, Agfa Healthcare, Leica Biosystems, Pathcore, Definiens, Hamamatsu, and Huron Digital PathologyThe digital pathology market is projected to grow at an 8.24% CAGR from 2025 to 2032, surpassing a valuation of approximately USD 5 billion. Growth is driven by AI integration, telepathology, and increasing demand for efficient diagnostics, with key players including Sectra, Proscia, and Agfa Healthcare.openPR.comDigital Pathology Market Innovations and Key Players: Roche, Visiopharm, Agfa Healthcare, 3D Histech, Definiens, Hamamatsu, Philips, Ventana Medical SystemsThe digital pathology market is expanding with AI and machine learning integration, driven by sustainability and demand for efficient diagnostics. Human pathology is the largest segment, with teleconsultation gaining momentum post-pandemic. Key players include Roche, Visiopharm, and Philips, while challenges include regulatory constraints and talent shortages.GlobeNewswireMEDIMMUNE ACQUIRES DEFINIENSMedImmune agreed to acquire Definiens for $150 million plus milestone payments, gaining its Tissue Phenomics imaging technology. The deal aims to improve biomarker identification in immuno-oncology, with closing expected in Q4 2014.FinSMEsDefiniens Closes €15M FinancingDefiniens AG closed a €15M financing round led by Wellington Partners and Gilde Healthcare, with participation from existing investors. The funds will support global growth in digital pathology and expansion into digital tissue diagnostics, including Tissue Phenomics strategy investments. The company plans to advance cancer diagnosis and treatment partnerships.FinSMEsDefiniens AG Raises 10M in FundingDefiniens AG raised €10m in funding led by Gilde Healthcare Partners, with participation from TVM, Cipio, and management. The Munich-based digital pathology company will use the funds for commercial expansion and developing new products. Dr Janke Dittmer joined the supervisory board.